Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.64 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.62 |
| ▸ | TACR1 | P25103 | 3/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337287 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL5916913 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL4949767 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL2736202 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL9421829 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL15241328 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL12249402 | 0.92 | TRPM8 (0.59) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL7221074 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL12249357 | 0.92 | TRPM8 (0.59) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL6925966 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3150586-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| EP-3112355-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2487165-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2487162-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487163-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487161-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2487166-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2170851-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009008989-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-6503898-B1 | Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-0686151-B1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DU PONT PHARM CO (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0858999-A1 | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5543517-A | VIRICIDES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | TRPM8 4728/4885CTRB1 177/4885TACR1 2739/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | TRPM8 1976/4885CTRB1 828/4885TACR1 485/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | TRPM8 1938/4885CTRB1 759/4885TACR1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.